NASDAQ:AKER Akers Biosciences - AKER Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$1.54▼$1.6150-Day Range$2.47▼$4.5952-Week Range$1.65▼$6.97Volume660,943 shsAverage Volume769,876 shsMarket Capitalization$25.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Akers Biosciences (NASDAQ:AKER) StockAkers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.Read More Receive AKER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKER Stock News HeadlinesMarch 15, 2023 | marketwatch.comRapid Tests Market Application, Product, Sales and Forecast 2023-2028March 12, 2023 | marketwatch.comGlobal Rapid Tests Market to by In-depth Analysis of Revenue Forecast and Competitive Landscape 2030 By VMReportsMarch 28, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 1, 2023 | marketwatch.com2023-2029 Cholesterol Testing Market Size and Growth Analysis | Research Report by Absolute ReportsFebruary 28, 2023 | msn.comStylist Zerina Akers’ Best Career Advice for Young Creatives: ‘Just Be Nice’February 23, 2023 | marketwatch.comGlobal Breath Analyzer Devices Market Size Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2030 By VMReportsFebruary 21, 2023 | marketwatch.comGlobal Non- Invasive Biosensors Market 2023 Industry Size, Share, Trends, Opportunities, Growth Analysis and Forecast to 2030 By VMReportsFebruary 20, 2023 | marketwatch.comRapid Tests Market Size, Share and Forecast 2028 with Top Countries DataMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 9, 2023 | marketwatch.comAlco-Sensor FST Market Research 2023 : Growth, Trends, Outlook and Future Scope Analysis 2028January 25, 2023 | marketwatch.comOral Anticoagulant Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataJanuary 23, 2023 | marketwatch.comCholesterol Testing Market to Receive Overwhelming Hike in Revenues by 2030 With key Players Abbott Diagnostics, Inc., AccuTech, LLCJanuary 9, 2023 | msn.comCam Akers Finishes Season On Three-Game 100-Yard StreakJanuary 8, 2023 | msn.comFamily of Akers Way 'hit and run' victim reveal plans for road safety campaignJanuary 7, 2023 | msn.comCam Akers Could Continue Rushing Hot Streak In Week 18January 4, 2023 | msn.com'Noles in the Pros: Week 17, Akers stays hot as he battles Samuel Jr.January 2, 2023 | msn.comWatch highlights from Cam Akers' huge game vs. ChargersJanuary 2, 2023 | msn.comCam Akers Starts a Rams Streak That Hasn't Been Hit Since 2018January 2, 2023 | msn.comSean McVay shares what's impressed him about Cam Akers during recent stretchJanuary 2, 2023 | msn.comCam Akers Offers Hope For Rams Running Game in Blowout Chargers LossJanuary 2, 2023 | msn.comRams RB Cam Akers continues late-season surge with another 100-yard performanceJanuary 2, 2023 | msn.comCam Akers is making Rams' decision at RB much easier in 2023December 31, 2022 | forbes.comLos Angeles Rams’ Cam Akers Is Finding Plenty Of Green After Escaping Sean McVay’s DoghouseDecember 30, 2022 | msn.comCam Akers An RB2 With RB1 UpsideDecember 30, 2022 | theramswire.usatoday.comCam Akers player props odds, tips and betting trends for Week 17 | Rams vs. ChargersDecember 29, 2022 | msn.comSean McVay Sees Cam Akers In Rams’ Long-Term PlansDecember 29, 2022 | msn.comCam Akers May Stick Around In LASee More Headlines Receive AKER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKER Company Calendar Last Earnings11/15/2018Today3/28/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic Substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKER CUSIPN/A CIK1321834 Webwww.akersbio.com Phone856 848 8698FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.42% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$1.58 million Price / Sales16.44 Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.29Miscellaneous Outstanding Shares16,653,000Free FloatN/AMarket Cap$25.98 million OptionableNot Optionable Beta0.30 Key ExecutivesMr. Christopher C. Schreiber (Age 56)CEO, Pres & Director Comp: $507.62kMr. Ian Rhodes (Age 48)Interim Chief Financial Officer Mr. Gary M. Rauch (Age 65)VP of Fin. & Treasurer Key CompetitorsOncoCyteNASDAQ:OCXARCA biopharmaNASDAQ:ABIOBiomericaNASDAQ:BMRANymox PharmaceuticalNASDAQ:NYMXTrinity BiotechNASDAQ:TRIBView All Competitors AKER Stock - Frequently Asked Questions How were Akers Biosciences' earnings last quarter? Akers Biosciences, Inc. (NASDAQ:AKER) released its quarterly earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter. What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO? 3 employees have rated Akers Biosciences Chief Executive Officer Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among the company's employees. What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioPharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL). What is Akers Biosciences' stock symbol? Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER." What is Akers Biosciences' stock price today? One share of AKER stock can currently be purchased for approximately $1.56. How much money does Akers Biosciences make? Akers Biosciences (NASDAQ:AKER) has a market capitalization of $25.98 million and generates $1.58 million in revenue each year. How can I contact Akers Biosciences? Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The official website for the company is www.akersbio.com. The medical instruments supplier can be reached via phone at 856 848 8698 or via email at investors@akersbio.com. This page (NASDAQ:AKER) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.